Jinhe Biotechnology Co. Ltd.
Shenzhen Stock ExchangeTotal Valuation
Jinhe Biotechnology Co. Ltd. carries a market capitalization of 3.81B, placing it among publicly traded companies globally. Its enterprise value stands at 6.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.81B |
| Enterprise Value | 6.42B |
Share Statistics
Jinhe Biotechnology Co. Ltd. currently has 769.50M shares outstanding.
| Shares Outstanding | 769.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jinhe Biotechnology Co. Ltd. trades at a trailing price-to-earnings ratio of 118.88. The price-to-sales ratio is 1.90, and the price-to-book ratio stands at 3.28.
| PE Ratio | 118.88 |
| PS Ratio | 1.90 |
| PB Ratio | 3.28 |
| P/TBV Ratio | 2.88 |
| P/FCF Ratio | 17.70 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jinhe Biotechnology Co. Ltd. trades at an EV/EBITDA multiple of 19.18 and an EV/FCF ratio of 24.86. The EV/Sales ratio of 2.73 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.18 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.73 |
| EV / EBITDA | 19.18 |
| EV / EBIT | 19.18 |
| EV / FCF | 24.86 |
Financial Position
Jinhe Biotechnology Co. Ltd. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 102.92, indicating elevated leverage, while an interest coverage ratio of 3.97 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.30 |
| Quick Ratio | 0.45 |
| Debt / Equity | 102.92 |
| Debt / EBITDA | 7.69 |
| Interest Coverage | 3.97 |
Financial Efficiency
Jinhe Biotechnology Co. Ltd. posts a return on equity of 2.72 and a return on invested capital of 0.45.
| Return on Equity (ROE) | 2.72 |
| Return on Assets (ROA) | 0.65 |
| Return on Invested Capital (ROIC) | 0.45 |
| Return on Capital Employed (ROCE) | 1.89 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.22 |
Taxes
Over the trailing twelve months, Jinhe Biotechnology Co. Ltd. has paid 51.65M in income taxes, reflecting an effective tax rate of 93.24.
| Income Tax | 51.65M |
| Effective Tax Rate | 93.24 |
Stock Price Statistics
Jinhe Biotechnology Co. Ltd.'s stock has declined approximately -25.11346% over the past 52 weeks. The 50-day moving average sits at 5.43, while the 200-day moving average is 6.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -25.11346% |
| 50-Day Moving Average | 5.43 |
| 200-Day Moving Average | 6.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jinhe Biotechnology Co. Ltd. generated 2.35B in revenue and converted that into 37.59M in net income, yielding earnings per share of 0.00. EBITDA reached 334.60M, while operating income came in at 334.60M.
| Revenue | 2.35B |
| Gross Profit | 806.72M |
| Operating Income | 334.60M |
| Pretax Income | 55.39M |
| Net Income | 37.59M |
| EBITDA | 334.60M |
| EBIT | 334.60M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Jinhe Biotechnology Co. Ltd. holds 839.24M in cash and equivalents against 2.57B in total debt, resulting in a net debt position of 959.90M. Total book value stands at 1.36B, with working capital of 549.74M providing operational flexibility.
| Cash & Cash Equivalents | 839.24M |
| Total Debt | 2.57B |
| Net Debt | 959.90M |
| Equity (Book Value) | 1.36B |
| Book Value Per Share | 1.77 |
| Working Capital | 549.74M |
Cash Flow
After subtracting -252.42M in capital expenditures, free cash flow totaled -252.42M - equivalent to -0.33 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -252.42M |
| Free Cash Flow | -252.42M |
| FCF Per Share | -0.33 |
Margins
Jinhe Biotechnology Co. Ltd. operates with a gross margin of 34.34, reflecting its pricing power and cost economics. The operating margin of 14.25 and net profit margin of 1.60 provide insight into operational efficiency.
| Gross Margin | 34.34 |
| Operating Margin | 14.25 |
| Pretax Margin | 2.36 |
| Profit Margin | 1.60 |
| EBITDA Margin | 14.25 |
Dividends & Yields
The company's payout ratio of -421.78 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.17 |
| Dividend Yield | N/A |
| Payout Ratio | -421.78 |
| Shareholder Yield | -8.45 |
| FCF Yield | 5.65 |
Stock Splits
Jinhe Biotechnology Co. Ltd.'s most recent stock split took place on May 17, 2016 with a 2:5 split ratio.
| Last Split Date | 5/17/2016 |
| Split Ratio | 2:5 |
Scores
Jinhe Biotechnology Co. Ltd. posts an Altman Z-Score of 1.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.82 |